Global Diabetic Retinopathy Market

Global Diabetic Retinopathy Market Size, Share, Growth Analysis, By Type(Proliferative Diabetic Retinopathy, and Non-proliferative diabetic retinopathy), By Management(Anti-VEGF, Intraocular Steroid Injection) - Industry Forecast 2024-2031

Report ID: SQMIG35A2516 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 63 | Figures: 75

Global Diabetic Retinopathy Market Competitive Landscape

To increase their market position, major players are focused on collaborations, partnerships, acquisitions, and other strategic operations. Industry leaders face growing competition with novel medication launches and regulatory approval of innovative management treatments, making it challenging for them to remain competitive in an ever-changing industry. However, market leaders' large investments in R&D are predicted to enhance market growth.

Eyenuk, a worldwide artificial intelligence (AI) healthcare company as well as the market leader in practical applications for AI Eye Evaluation and AI Predictive Biomarkers, will be able to market its EyeArt AI retinal screening device throughout the European Union in January 2023 for new uses such as identifying AMD (age-related macular degeneration) and glaucomatous damage to the optic nerve (a sign of glaucoma).

Top Player’s Company Profiles in Global Diabetic Retinopathy Market

  • Novartis AG
  • Roche Holding AG
  • Bayer AG
  • Regeneron Pharmaceuticals, Inc.
  • Allergan plc (AbbVie Inc.)
  • Carl Zeiss Meditec AG
  • Topcon Corporation
  • Nidek Co., Ltd.
  • Optos plc (Nikon Corporation)
  • Bausch Health Companies Inc.
  • Alcon Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Lumenis Ltd. (XIO Group)
  • Iridex Corporation
  • Leica Microsystems (Danaher Corporation)
  • StemCells Inc. (Microbot Medical Inc.)
  • Bioptigen, Inc. (Metabolic Technologies Inc.)
  • CenterVue SpA
  • Visunex Medical Systems, Inc.
  • Clarity Medical Systems, Inc.

Global Diabetic Retinopathy Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Diabetic Retinopathy Market size was valued at USD 8.30 billion in 2022 and is poised to grow from USD 8.83 billion in 2023 to USD 14.51 billion by 2031, growing at a CAGR of 6.4% during the forecast period (2024-2031).

To increase their market position, major players are focused on collaborations, partnerships, acquisitions, and other strategic operations. Industry leaders face growing competition with novel medication launches and regulatory approval of innovative management treatments, making it challenging for them to remain competitive in an ever-changing industry. However, market leaders' large investments in R&D are predicted to enhance market growth. 'Novartis AG', 'Roche Holding AG', 'Bayer AG', 'Regeneron Pharmaceuticals, Inc.', 'Allergan plc (AbbVie Inc.)', 'Carl Zeiss Meditec AG', 'Topcon Corporation', 'Nidek Co., Ltd.', 'Optos plc (Nikon Corporation)', 'Bausch Health Companies Inc.', 'Alcon Inc.', 'Santen Pharmaceutical Co., Ltd.', 'Lumenis Ltd. (XIO Group)', 'Iridex Corporation', 'Leica Microsystems (Danaher Corporation)', 'StemCells Inc. (Microbot Medical Inc.)', 'Bioptigen, Inc. (Metabolic Technologies Inc.)', 'CenterVue SpA', 'Visunex Medical Systems, Inc.', 'Clarity Medical Systems, Inc.'

Increasing Emphasis on Early Detection and Intervention: There is a growing recognition of the importance of early detection and intervention in diabetic retinopathy. The focus is shifting towards regular screening programs, awareness campaigns, and advanced imaging technologies for early diagnosis, enabling timely treatment and better management of the condition.

North America dominated the market, accounting for 37.8% of total revenue in 2022. Some of the market's drivers include the presence of modern healthcare infrastructure, favorable government activities pertaining to medication research, and the presence of substantial patient & practitioner awareness levels. One of the primary factors contributing to this region's huge share is the high market penetration of new goods such as anti-VEGF medications such as Lucentis, Avastin, and Eylea. High healthcare expenditure, increased patient knowledge of diabetes, the availability of well-established medical facilities, and a favorable reimbursement environment are some of the primary causes.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Diabetic Retinopathy Market

Report ID: SQMIG35A2734 | Region: Global | Published Date: March, 2024 | Pages: 219 | Tables: 67 | Figures: 80

Global Muscle Stimulation Devices Market
Buy Now GET FREE SAMPLE
Global Diabetic Retinopathy Market

Report ID: UCMIG35A2488 | Region: Global | Published Date: March, 2024 | Pages: 165 | Tables: Figures:

Women's Health Diagnostics Market
Buy Now GET FREE SAMPLE
Global Diabetic Retinopathy Market

Report ID: UCMIG35A2673 | Region: Global | Published Date: March, 2024 | Pages: 165 | Tables: Figures:

Periodontal Scalers And Curettes Market
Buy Now GET FREE SAMPLE
Global Diabetic Retinopathy Market

Report ID: SQMIG35A2684 | Region: Global | Published Date: March, 2024 | Pages: 157 | Tables: 59 | Figures: 75

Global X-Ray Flat Panel Detectors Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Diabetic Retinopathy Market

Product ID: SQMIG35A2516

$5,300
BUY NOW GET FREE SAMPLE